Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Older Adults' Reasons for Participating in an eHealth Prevention Trial: A Cross-Country, Mixed-Methods Comparison.

Coley N, Rosenberg A, van Middelaar T, Soulier A, Barbera M, Guillemont J, Steensma J, Igier V, Eskelinen M, Soininen H, Moll van Charante E, Richard E, Kivipelto M, Andrieu S; MIND-AD; HATICE groups.

J Am Med Dir Assoc. 2018 Dec 9. pii: S1525-8610(18)30599-1. doi: 10.1016/j.jamda.2018.10.019. [Epub ahead of print]

PMID:
30541689
2.

Ion mobility-mass spectrometry analysis of diarylquinoline diastereomers: Drugs used for tuberculosis treatment.

Domalain V, Hubert-Roux M, Quéguiner L, Fouque DJ, Arnoult E, Speybrouck D, Guillemont J, Afonso C.

Eur J Mass Spectrom (Chichester). 2018 Dec 5:1469066718813226. doi: 10.1177/1469066718813226. [Epub ahead of print]

PMID:
30518251
3.

Designing an Internet-Based Multidomain Intervention for the Prevention of Cardiovascular Disease and Cognitive Impairment in Older Adults: The HATICE Trial.

Barbera M, Mangialasche F, Jongstra S, Guillemont J, Ngandu T, Beishuizen C, Coley N, Brayne C, Andrieu S, Richard E, Soininen H, Kivipelto M; HATICE study group.

J Alzheimers Dis. 2018;62(2):649-663. doi: 10.3233/JAD-170858.

PMID:
29480185
4.

Engaging older people in an internet platform for cardiovascular risk self-management: a qualitative study among Dutch HATICE participants.

van Middelaar T, Beishuizen CRL, Guillemont J, Barbera M, Richard E, Moll van Charante EP; HATICE consortium.

BMJ Open. 2018 Jan 21;8(1):e019683. doi: 10.1136/bmjopen-2017-019683.

5.

Synthesis and evaluation of analogues of the tuberculosis drug bedaquiline containing heterocyclic B-ring units.

Choi PJ, Sutherland HS, Tong AST, Blaser A, Franzblau SG, Cooper CB, Lotlikar MU, Upton AM, Guillemont J, Motte M, Queguiner L, Andries K, Van den Broeck W, Denny WA, Palmer BD.

Bioorg Med Chem Lett. 2017 Dec 1;27(23):5190-5196. doi: 10.1016/j.bmcl.2017.10.042. Epub 2017 Oct 20.

6.

6-Cyano Analogues of Bedaquiline as Less Lipophilic and Potentially Safer Diarylquinolines for Tuberculosis.

Tong AST, Choi PJ, Blaser A, Sutherland HS, Tsang SKY, Guillemont J, Motte M, Cooper CB, Andries K, Van den Broeck W, Franzblau SG, Upton AM, Denny WA, Palmer BD, Conole D.

ACS Med Chem Lett. 2017 Sep 22;8(10):1019-1024. doi: 10.1021/acsmedchemlett.7b00196. eCollection 2017 Oct 12.

7.

Improving data sharing in research with context-free encoded missing data.

Hoevenaar-Blom MP, Guillemont J, Ngandu T, Beishuizen CRL, Coley N, Moll van Charante EP, Andrieu S, Kivipelto M, Soininen H, Brayne C, Meiller Y, Richard E.

PLoS One. 2017 Sep 12;12(9):e0182362. doi: 10.1371/journal.pone.0182362. eCollection 2017.

8.

Effectiveness of a web-based intervention to reduce alcohol consumption among French hazardous drinkers: a randomized controlled trial.

Guillemont J, Cogordan C, Nalpas B, Nguyen-Thanh V, Richard JB, Arwidson P.

Health Educ Res. 2017 Aug 1;32(4):332-342. doi: 10.1093/her/cyx052.

PMID:
28854571
9.

Development and Validation of an Interactive Internet Platform for Older People: The Healthy Ageing Through Internet Counselling in the Elderly Study.

Jongstra S, Beishuizen C, Andrieu S, Barbera M, van Dorp M, van de Groep B, Guillemont J, Mangialasche F, van Middelaar T, Moll van Charante P, Soininen H, Kivipelto M, Richard E.

Telemed J E Health. 2017 Feb;23(2):96-104. doi: 10.1089/tmj.2016.0066. Epub 2016 Jul 27.

PMID:
27463120
10.

Healthy Ageing Through Internet Counselling in the Elderly: the HATICE randomised controlled trial for the prevention of cardiovascular disease and cognitive impairment.

Richard E, Jongstra S, Soininen H, Brayne C, Moll van Charante EP, Meiller Y, van der Groep B, Beishuizen CR, Mangialasche F, Barbera M, Ngandu T, Coley N, Guillemont J, Savy S, Dijkgraaf MG, Peters RJ, van Gool WA, Kivipelto M, Andrieu S.

BMJ Open. 2016 Jun 10;6(6):e010806. doi: 10.1136/bmjopen-2015-010806.

11.

Structure of the mycobacterial ATP synthase Fo rotor ring in complex with the anti-TB drug bedaquiline.

Preiss L, Langer JD, Yildiz Ö, Eckhardt-Strelau L, Guillemont JE, Koul A, Meier T.

Sci Adv. 2015 May 8;1(4):e1500106. doi: 10.1126/sciadv.1500106. eCollection 2015 May.

12.

Effects of alcoholic beverage control policies and contextual factors on alcohol consumption and its related harms in France from 1960 to 2000.

Cogordan C, Kreft-Jaïs C, Guillemont J.

Subst Use Misuse. 2014 Oct;49(12):1633-45. doi: 10.3109/10826084.2014.913391. Epub 2014 Jun 10.

PMID:
24915170
13.

[Evidence-based and promising interventions to prevent alcohol use among youth: a literature review].

Guillemont J, Clément J, Cogordan C, Lamboy B.

Sante Publique. 2013 Jan-Feb;25 Suppl 1:37-45. Review. French.

PMID:
23782634
14.

Novel antibiotics targeting respiratory ATP synthesis in Gram-positive pathogenic bacteria.

Balemans W, Vranckx L, Lounis N, Pop O, Guillemont J, Vergauwen K, Mol S, Gilissen R, Motte M, Lançois D, De Bolle M, Bonroy K, Lill H, Andries K, Bald D, Koul A.

Antimicrob Agents Chemother. 2012 Aug;56(8):4131-9. doi: 10.1128/AAC.00273-12. Epub 2012 May 21.

15.

[Evidence-based interventions in youth mental health prevention and promotion].

Lamboy B, Clément J, Saïas T, Guillemont J.

Sante Publique. 2011 Nov-Dec;23 Suppl 6:S113-25. Review. French.

PMID:
22370077
16.

Difluoromethylbenzoxazole pyrimidine thioether derivatives: a novel class of potent non-nucleoside HIV-1 reverse transcriptase inhibitors.

Boyer J, Arnoult E, Médebielle M, Guillemont J, Unge J, Jochmans D.

J Med Chem. 2011 Dec 8;54(23):7974-85. doi: 10.1021/jm200766b. Epub 2011 Nov 4.

PMID:
22017513
17.

Diarylquinolines, synthesis pathways and quantitative structure--activity relationship studies leading to the discovery of TMC207.

Guillemont J, Meyer C, Poncelet A, Bourdrez X, Andries K.

Future Med Chem. 2011 Sep;3(11):1345-60. doi: 10.4155/fmc.11.79.

PMID:
21879841
18.

Probing the interaction of the diarylquinoline TMC207 with its target mycobacterial ATP synthase.

Haagsma AC, Podasca I, Koul A, Andries K, Guillemont J, Lill H, Bald D.

PLoS One. 2011;6(8):e23575. doi: 10.1371/journal.pone.0023575. Epub 2011 Aug 17.

19.

The challenge of new drug discovery for tuberculosis.

Koul A, Arnoult E, Lounis N, Guillemont J, Andries K.

Nature. 2011 Jan 27;469(7331):483-90. doi: 10.1038/nature09657. Review.

PMID:
21270886
20.

Essentiality of FASII pathway for Staphylococcus aureus.

Balemans W, Lounis N, Gilissen R, Guillemont J, Simmen K, Andries K, Koul A.

Nature. 2010 Jan 21;463(7279):E3; discussion E4. doi: 10.1038/nature08667.

PMID:
20090698
21.

[R207910 (TMC207): a new antibiotic for the treatment of tuberculosis].

Lounis N, Guillemont J, Veziris N, Koul A, Jarlier V, Andries K.

Med Mal Infect. 2010 Jul;40(7):383-90. doi: 10.1016/j.medmal.2009.09.007. Epub 2009 Dec 1. Review. French.

PMID:
19954909
22.

Alcohol as a risk factor for injury: lessons from French data.

Guillemont J, Girard D, Arwidson P, Basset B.

Int J Inj Contr Saf Promot. 2009 Jun;16(2):81-7. doi: 10.1080/17457300902836655.

PMID:
19941203
23.

Synthesis and biological evaluation of C-5 methyl substituted 4-arylthio and 4-aryloxy-3-Iodopyridin-2(1H)-one type anti-HIV agents.

Guillemont J, Benjahad A, Oumouch S, Decrane L, Palandjian P, Vernier D, Queguiner L, Andries K, de Béthune MP, Hertogs K, Grierson DS, Nguyen CH.

J Med Chem. 2009 Dec 10;52(23):7473-87. doi: 10.1021/jm900802y.

PMID:
19645483
24.

MurF inhibitors with antibacterial activity: effect on muropeptide levels.

Baum EZ, Crespo-Carbone SM, Foleno BD, Simon LD, Guillemont J, Macielag M, Bush K.

Antimicrob Agents Chemother. 2009 Aug;53(8):3240-7. doi: 10.1128/AAC.00166-09. Epub 2009 May 26.

25.

Diastereodivergent addition of allenylzincs to aryl glyoxylates.

Hameury T, Guillemont J, Van Hijfte L, Bellosta V, Cossy J.

Org Lett. 2009 Jun 4;11(11):2397-400. doi: 10.1021/ol900494g.

PMID:
19422262
26.

Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue.

Haagsma AC, Abdillahi-Ibrahim R, Wagner MJ, Krab K, Vergauwen K, Guillemont J, Andries K, Lill H, Koul A, Bald D.

Antimicrob Agents Chemother. 2009 Mar;53(3):1290-2. doi: 10.1128/AAC.01393-08. Epub 2008 Dec 15.

27.

Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis.

Koul A, Vranckx L, Dendouga N, Balemans W, Van den Wyngaert I, Vergauwen K, Göhlmann HW, Willebrords R, Poncelet A, Guillemont J, Bald D, Andries K.

J Biol Chem. 2008 Sep 12;283(37):25273-80. doi: 10.1074/jbc.M803899200. Epub 2008 Jul 14.

28.

School-based behavioral assessment tools are reliable and valid for measurement of fruit and vegetable intake, physical activity, and television viewing in young children.

Economos CD, Sacheck JM, Kwan Ho Chui K, Irizarry L, Guillemont J, Collins JJ, Hyatt RR.

J Am Diet Assoc. 2008 Apr;108(4):695-701. doi: 10.1016/j.jada.2008.01.001. Erratum in: J Am Diet Assoc. 2008 Nov;108(11):1936. Irizzary, Laura [corrected to Irizarry, Laura].

PMID:
18375228
29.

Selection of a respiratory syncytial virus fusion inhibitor clinical candidate, part 1: improving the pharmacokinetic profile using the structure-property relationship.

Bonfanti JF, Doublet F, Fortin J, Lacrampe J, Guillemont J, Muller P, Queguiner L, Arnoult E, Gevers T, Janssens P, Szel H, Willebrords R, Timmerman P, Wuyts K, Janssens F, Sommen C, Wigerinck P, Andries K.

J Med Chem. 2007 Sep 20;50(19):4572-84. Epub 2007 Aug 28.

PMID:
17722899
30.

Diarylquinolines target subunit c of mycobacterial ATP synthase.

Koul A, Dendouga N, Vergauwen K, Molenberghs B, Vranckx L, Willebrords R, Ristic Z, Lill H, Dorange I, Guillemont J, Bald D, Andries K.

Nat Chem Biol. 2007 Jun;3(6):323-4. Epub 2007 May 13.

PMID:
17496888
31.

A computational model of the inhibition of Mycobacterium tuberculosis ATPase by a new drug candidate R207910.

de Jonge MR, Koymans LH, Guillemont JE, Koul A, Andries K.

Proteins. 2007 Jun 1;67(4):971-80.

PMID:
17387738
32.

Synthesis of novel diarylpyrimidine analogues of TMC278 and their antiviral activity against HIV-1 wild-type and mutant strains.

Mordant C, Schmitt B, Pasquier E, Demestre C, Queguiner L, Masungi C, Peeters A, Smeulders L, Bettens E, Hertogs K, Heeres J, Lewi P, Guillemont J.

Eur J Med Chem. 2007 May;42(5):567-79. Epub 2006 Dec 15.

PMID:
17223230
33.

Structure-activity relationship in the 3-iodo-4-phenoxypyridinone (IOPY) series: The nature of the C-3 substituent on anti-HIV activity.

Benjahad A, Oumouch S, Guillemont J, Pasquier E, Mabire D, Andries K, Nguyen CH, Grierson DS.

Bioorg Med Chem Lett. 2007 Feb 1;17(3):712-6. Epub 2006 Nov 1.

PMID:
17157017
34.

Conformational analysis of r207910, a new drug candidate for the treatment of tuberculosis, by a combined NMR and molecular modeling approach.

Gaurrand S, Desjardins S, Meyer C, Bonnet P, Argoullon JM, Oulyadi H, Guillemont J.

Chem Biol Drug Des. 2006 Aug;68(2):77-84.

PMID:
16999772
35.

Crystal structures for HIV-1 reverse transcriptase in complexes with three pyridinone derivatives: a new class of non-nucleoside inhibitors effective against a broad range of drug-resistant strains.

Himmel DM, Das K, Clark AD Jr, Hughes SH, Benjahad A, Oumouch S, Guillemont J, Coupa S, Poncelet A, Csoka I, Meyer C, Andries K, Nguyen CH, Grierson DS, Arnold E.

J Med Chem. 2005 Dec 1;48(24):7582-91.

PMID:
16302798
36.

Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1.

Guillemont J, Pasquier E, Palandjian P, Vernier D, Gaurrand S, Lewi PJ, Heeres J, de Jonge MR, Koymans LM, Daeyaert FF, Vinkers MH, Arnold E, Das K, Pauwels R, Andries K, de Béthune MP, Bettens E, Hertogs K, Wigerinck P, Timmerman P, Janssen PA.

J Med Chem. 2005 Mar 24;48(6):2072-9.

PMID:
15771449
37.

4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones: in vitro evaluation of new C-3-amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strains.

Benjahad A, Croisy M, Monneret C, Bisagni E, Mabire D, Coupa S, Poncelet A, Csoka I, Guillemont J, Meyer C, Andries K, Pauwels R, de Béthune MP, Himmel DM, Das K, Arnold E, Nguyen CH, Grierson DS.

J Med Chem. 2005 Mar 24;48(6):1948-64.

PMID:
15771439
38.

In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine).

Janssen PA, Lewi PJ, Arnold E, Daeyaert F, de Jonge M, Heeres J, Koymans L, Vinkers M, Guillemont J, Pasquier E, Kukla M, Ludovici D, Andries K, de Béthune MP, Pauwels R, Das K, Clark AD Jr, Frenkel YV, Hughes SH, Medaer B, De Knaep F, Bohets H, De Clerck F, Lampo A, Williams P, Stoffels P.

J Med Chem. 2005 Mar 24;48(6):1901-9. Review.

PMID:
15771434
39.

A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis.

Andries K, Verhasselt P, Guillemont J, Göhlmann HW, Neefs JM, Winkler H, Van Gestel J, Timmerman P, Zhu M, Lee E, Williams P, de Chaffoy D, Huitric E, Hoffner S, Cambau E, Truffot-Pernot C, Lounis N, Jarlier V.

Science. 2005 Jan 14;307(5707):223-7. Epub 2004 Dec 9.

40.

4-benzyl- and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family of potent anti-HIV agents: optimization and in vitro evaluation against clinically important HIV mutant strains.

Benjahad A, Courté K, Guillemont J, Mabire D, Coupa S, Poncelet A, Csoka I, Andries K, Pauwels R, de Béthune MP, Monneret C, Bisagni E, Nguyen CH, Grierson DS.

J Med Chem. 2004 Oct 21;47(22):5501-14.

PMID:
15481987
41.

3-iodo-4-phenoxypyridinones (IOPY's), a new family of highly potent non-nucleoside inhibitors of HIV-1 reverse transcriptase.

Benjahad A, Guillemont J, Andries K, Nguyen CH, Grierson DS.

Bioorg Med Chem Lett. 2003 Dec 15;13(24):4309-12.

PMID:
14643315

Supplemental Content

Loading ...
Support Center